[Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000097:blood; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D008750:Methyldopa / Q000008:administration & dosage* / Q000097:blood; D010300:Parkinson Disease / Q000188:drug therapy*; D010648:Phenylacetates / Q000097:blood; D013997:Time Factors
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004338:Drug Combinations; D010648:Phenylacetates; D008750:Methyldopa; D004295:Dihydroxyphenylalanine
Thérapeutique des syndromes parkinsoniens et taux de DOPA plasmatique. Effets de la L-DOPA et de la 3-OMD, administrées seules ou combinées, avec ou sans inhibiteur de la décarboxylase.